Sophia Antipolis, France

Press release – For immediate release – 5:45 pm CET

Financial Communications Schedule for the First Half of 2024

Median Technologies (FR0011049824, ALMDT, PEA/SME eligible), announces the publication date for its 2023 results:

2023 ResultsApril 25, 2024
Distribution after the close of trading
Download 20240122_PR_FiComS12024_EN.pdf

About Median Technologies

Pioneering in innovative imaging solutions and services, Median Technologies harnesses cutting-edge AI to elevate the accuracy of early cancer and metabolic disease diagnoses and treatments. Median’s offerings, including iCRO for medical image analysis and management in oncology trials and eyonis™, AI/ML tech-based suite of software as medical devices (SaMD), empower biopharmaceutical entities and clinicians to advance patient care and expedite novel therapies. Since its inception, the French-based company, with a presence in the U.S. and China, has been recognized as an “Innovative company” by BPI France and trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is eligible for the French SME equity savings plan scheme (PEA-PME).



Median Technologies
Emmanuelle Leygues
Head of Corporate Marketing and Financial Communications
+33 6 10 93 58 88

Press – ALIZE RP
Caroline Carmagnol
+33 6 64 18 99 59

Investors – ACTIFIN
Ghislaine Gasparetto
+33 6 21 10 49 24